Search Our Scientific Publications & Authors

Ophthalmic Res 2019 Apr 23:1-8. Epub 2019 Apr 23.

AIBILI, Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal,

Purpose: This study is aimed at characterizing the type of retinal edema in the initial stages of retinopathy in type 2 diabetes.

Methods: In this retrospective cross-sectional study, spectral domain optical coherence tomography (OCT) layer by layer analysis of the retina in association with OCT-Leakage, an algorithm to detect sites of low optical reflectivity, were used to examine eyes with minimal, mild, and moderate diabetic retinopathy (DR).

Results: A total of 142 eyes from 142 patients (28% women) aged 52-88 years were imaged. Read More

Cutan Ocul Toxicol 2019 Apr 22:1-24. Epub 2019 Apr 22.

a Department of Ophthalmology, Faculty of Medicine , Afyonkarahisar Health Sciences University , Afyonkarahisar / TURKEY.

Purpose: To evaluate the effects of intravitreal aflibercept (IVA) treatment on retinal vein parameters and choroidal thickness used in the treatment of diabetic macular edema (DME).

Methods: This retrospective study administered Afyonkarahisar Health Sciences University Department of Ophthalmology. Twenty-nine patients who were diagnosed with naive DME in a single eye. Read More

J Korean Med Sci 2019 Apr 22;34(15):e118. Epub 2019 Apr 22.

Department of Ophthalmology, Daegu Catholic University Medical Center, Daegu, Korea.

Background: Limited data exist on real-world treatment patterns for diabetic macular edema (DME) in Korea. In this study, we investigated DME treatment patterns from 2009 to 2014 and the impact of baseline treatment on healthcare resource utilization and visual acuity (VA) outcomes.

Methods: A retrospective cohort chart review of DME patients treated at 11 hospital ophthalmology clinics between January 1, 2012 and December 31, 2013 was conducted. Read More

Prog Retin Eye Res 2019 Apr 15. Epub 2019 Apr 15.

University of Iceland, Reykjavik, Iceland.

Retinal oximetry imaging of retinal blood vessels measures oxygen saturation of hemoglobin. The imaging technology is non-invasive and reproducible with remarkably low variability on test-retest studies and in healthy cohorts. Pathophysiological principles and novel biomarkers in several retinal diseases have been discovered, as well as possible applications for systemic and brain disease. Read More

Curr Eye Res 2019 Apr 14. Epub 2019 Apr 14.

a Bagcilar Training and Research Hospital, Ophthalmology Department , Istanbul Health Sciences University , Istanbul , TURKEY.

Aim Of The Study: The aim of this study is to compare the efficacy of intravitreal injection of Aflibercept and Ranibizumab in the treatment of naive diabetic macular edema (DME) with serous retinal detachment (SRD).

Materials And Methods: In this prospective, non- randomized-cohort study, 60 eyes with DME with SRD were divided into two groups: group1 consisted of 30 eyes treated with intravitreal injection of 0.5 mg/0. Read More

Wien Klin Wochenschr 2019 Apr 12. Epub 2019 Apr 12.

Universitäts-Augenklinik, Medizinische Universität Graz, Graz, Österreich.

Diabetes mellitus can cause diabetic retinopathy, diabetic macular edema, optic neuropathy, cataract or dysfunction of the eye muscles. The incidence of these defects correlates with disease duration and quality of metabolic control. Recommendations of the Austrian Diabetes Association for diagnosis, therapeutic procedures and requirements for adequate follow-up depending on stage of diabetic eye disease are summarized. Read More

Korean J Ophthalmol 2019 Apr;33(2):198-199

Department of Ophthalmology, Kangwon National University School of Medicine, Chuncheon, Korea.

Korean J Ophthalmol 2019 Apr;33(2):122-130

Department of Ophthalmology, South Valley University, Qena, Egypt.

Purpose: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections.

Methods: A prospective interventional case series study recruited patients from a single center diagnosed with DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of aflibercept were performed. Read More

Can J Ophthalmol 2019 Apr 23;54(2):203-211. Epub 2018 Aug 23.

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont., Canada; Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ont., Canada.. Electronic address:

Background: There are currently low rates of screening for diabetic retinopathy (DR) and sight-threatening diabetic macular edema (DME) in Ontario.

Objective: To present results of the Toronto Tele-Retinal screening program for patients with diabetes mellitus and to evaluate thebenefit of optical coherence tomography (OCT) in combination with monoscopic colour fundus photographs for detection of DME.

Methods: All electronic medical records for adults with type I and II diabetes mellitus screened through the Toronto Tele-Retinal screening program between September 2013 to August 2017 across 7 sc~reening sites in urban and rural settings were reviewed. Read More

JAMA Ophthalmol 2019 Apr 11. Epub 2019 Apr 11.

National Institute for Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, United Kingdom.

Importance: Threshold of retinal nonperfusion for the development of proliferative diabetic retinopathy (PDR) is unclear.

Objectives: To identify a threshold of retinal nonperfusion for the presence of retinal neovascularization and the distribution and area of retinal nonperfusion in eyes with severe nonproliferative diabetic retinopathy (NPDR), PDR, neovascularization of the optic disc (NVD), and retinal neovascularization elsewhere (NVE).

Design, Setting, And Participants: This cross-sectional image analysis study was performed between September 24, 2018, and October 24, 2018, at a multicenter national study in the United Kingdom. Read More

Ophthalmol Ther 2019 Apr 10. Epub 2019 Apr 10.

Medical Retina Service, Moorfields Eye Hospital, London, UK.

Introduction: To report the 52-week treatment outcomes with intravitreal injections of aflibercept using a treat-and-extend regimen for treating macular edema secondary to central retinal vein occlusion (CRVO).

Methods: A retrospective analysis of patients newly diagnosed with CRVO was performed. Patients receiving aflibercept between 1 December 2016 and 31 March 2017 were included in the analysis. Read More

J Med Signals Sens 2019 Jan-Mar;9(1):1-14

Department of Bioelectric and Biomedical Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Background: Macular disorders, such as diabetic macular edema (DME) and age-related macular degeneration (AMD) are among the major ocular diseases. Having one of these diseases can lead to vision impairments or even permanent blindness in a not-so-long time span. So, the early diagnosis of these diseases are the main goals for researchers in the field. Read More

Am J Ophthalmol 2019 Apr 5. Epub 2019 Apr 5.

Department of Ophthalmology and Vision Sciences, University of Toronto, Canada; Department of Ophthalmology, St. Michael's Hospital, Canada. Electronic address:

Purpose: To determine the association of aqueous humor cytokine concentrations with long-term treatment response to anti-vascular endothelial growth factor (VEGF) agents in diabetic macular edema (DME).

Design: Retrospective case series.

Methods: Pooled data of aqueous humor cytokine concentrations collected at baseline and 2-month follow-up (2 injections) for treatment-naïve eyes with center-involving DME previously enrolled in a prospective study were reviewed. Read More

Am J Ophthalmol 2019 Apr 5. Epub 2019 Apr 5.

Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California, USA; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address:

Purpose: To classify retinal nonperfusion regions (NPR) in patients with diabetic macular edema (DME) and assess the relationship with severity of DME.

Design: Prospective, observational case series.

Methods: Forty eyes of 29 patients with treatment-naïve center-involved macular edema secondary to diabetes mellitus were included (The DAVE study, NCT01552408) in this analysis. Read More

Jpn J Ophthalmol 2019 Apr 6. Epub 2019 Apr 6.

Department of Ophthalmology, Aichi Medical University, 1-1 Yazako-Karimata, Nagakute, 480-1195, Aichi, Japan.

Purpose: To evaluate the efficacy and safety of intravitreal drug injections using a short 34-gauge needle.

Study Design: Retrospective study.

Methods: This study included patients with age-related macular degeneration, diabetic macular edema, or macular edema associated with retinal vein occlusion. Read More

Retina 2019 Apr 2. Epub 2019 Apr 2.

Kayseri City Hospital, Kocasinan, Kayseri, Turkey.

Purpose: To compare the efficacy and safety of intravitreal dexamethasone (DEX) implant versus aflibercept in patients with treatment-naive diabetic macular edema with inflammatory biomarkers.

Methods: Ninety-eight eyes of 62 treatment-naive patients with diabetic macular edema with serous retinal detachment and hyperreflective foci were enrolled. Each patient was randomized to receive either aflibercept or DEX implant treatment. Read More

J Interferon Cytokine Res 2019 Apr 5. Epub 2019 Apr 5.

1 Department and Clinic of Ophthalmology, University of Wrocław Medical College, Wrocław, Poland.

Interferon alpha (IFN-α) is a glycoprotein with antitumor, antiviral, and immunomodulatory activity, used widely in the treatment of viral infections (hepatitis B and C, condylomata acuminata, herpes zoster, etc.), hematological disorders (leukemia, multiple myeloma, T cell lymphoma, and essential thrombocythemia), and solid tumors (clear cell carcinoma in the metastatic stage, melanoma, hepatocellular carcinoma, and cervical neoplasia). Studies have proven the effectiveness of IFN-α in the treatment of ophthalmic disorders involving the anterior segment of the eye (conjunctival papilloma, squamous neoplasia, conjunctival mucosa-associated lymphoid tissue, Mooren's ulcer, and vernal keratoconjunctivitis) and the posterior segment of the eye (serpiginous choroidopathy, posterior uveitis, pseudophakic and diabetic cystoid macular edema, and proliferative diabetic retinopathy). Read More

J Ophthalmol 2019 4;2019:2073679. Epub 2019 Mar 4.

Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Purpose: To model a community-based telescreening program for diabetic retinopathy (DR) in Iran and to implement a pilot project at the Iranian Diabetes Society (IDS) branch in a Tehran suburb.

Methods: In this mixed model study, a web application called the "Iranian Retinopathy Teleophthalmology Screening (IRTOS)" was launched. The educational course for DR screening was established for general practitioners (GPs). Read More

Ophthalmology 2019 Apr 1. Epub 2019 Apr 1.

Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States.

Purpose: To evaluate changes in retinal perfusion status with intravitreal aflibercept injection (IAI) and laser treatment in the phase 3 VISTA study of patients with diabetic macular edema (DME).

Design: Post-hoc analysis of a double-masked, randomized, active-controlled, phase 3 trial.

Participants: Patients with center-involved DME in the study eye. Read More

Medicine (Baltimore) 2019 Apr;98(14):e14999

Department of Ophthalmology, First Affiliated Hospital of Jiamusi University.

Background: Numerous studies have reported the efficacy of fenofibrate for patients with diabetic retinopathy (DRP). No systematic review has, however, addressed its efficacy for DRP. Thus, this systematic review will firstly evaluate the efficacy and safety of fenofibrate for patients with DRP. Read More

Graefes Arch Clin Exp Ophthalmol 2019 Apr 1. Epub 2019 Apr 1.

Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, #150 Seongan-ro, Seoul, Gangdong-gu, 05355, South Korea.

Purpose: To compare serum and aqueous humor (AH) vitamin D levels between the patients with diabetic macular edema (DME) and controls.

Methods: A total of 65 subjects (30 DME, 35 control) were included. One-third of the control group had hypertension, dyslipidemia, or diabetes mellitus without diabetic retinopathy as underlying diseases. Read More

Invest Ophthalmol Vis Sci 2019 Apr;60(5):1336-1343

Institut Clínic d'Oftalmologia (ICOF), Hospital Clínic, Barcelona, Spain.

Purpose: To determine whether baseline cytokine aqueous humor (AH) levels are associated with diabetic macular edema (DME) anatomic response to dexamethasone intravitreal implant (DEX) injection.

Methods: This was a prospective cohort study of DME cases receiving DEX treatment. Seventy patients were recruited with center-involving DME with spectral-domain (SD) optical coherence tomography (OCT) detection of central macular thickness (CMT) ≥300 μm on macular cube 518 × 128-μm scan protocol (Cirrus SD-OCT). Read More

Ophthalmic Res 2019 Mar 29:1-10. Epub 2019 Mar 29.

Bordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, Bordeaux, France.

Purpose: To report the real-world effectiveness and safety of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME).

Methods: This is a French, 36-month, multicenter, observational cohort study. Read More

Int J Ophthalmol 2019 18;12(3):442-450. Epub 2019 Mar 18.

Department of Ophthalmology, Wuhan School of Clinical Medicine, Southern Medical University (Wuhan General Hospital of Guangzhou Military Region), Wuhan 430060, Hubei Province, China.

Aim: To investigate the incidence and subsequent changes of outer retinal tubulations (ORTs) in diabetic macular edema (DME) underwent anti-vascular endothelial growth factor (VEGF) therapy, and to assess the possibility of ORT as a biomarker of DME severity or response to anti-VEGF therapy.

Methods: This retrospective and descriptive study included a total of 228 patients (435 eyes) with DME and treated with intravitreal anti-VEGF agents between March 2016 and January 2018. Patients were divided into 2 groups according to the presence of ORTs. Read More

Int J Ophthalmol 2019 18;12(3):387-392. Epub 2019 Mar 18.

Mansoura Ophthlmic Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.

Aim: To evaluate the effect of prophylactic administration of nepafenac in prevention of macular edema occurring in diabetic patients after phacoemulsification and to investigate the correlation between optical coherence tomography (OCT) foveal thickness and multifocal electroretinogram (MF-ERG) parameters.

Methods: The study included two groups. Group 1 included 50 diabetic patients with senile cataract (50 eyes, 30 females, 20 males, aged 55±7y) received nepafenac 0. Read More

Sci Rep 2019 Mar 26;9(1):5164. Epub 2019 Mar 26.

Ophthalmology Service, Hospital Juarez de Mexico, Mexico, Mexico.

Photocoagulation may still be a therapeutic choice for center-sparing diabetic macular edema. We compared the visual evolution after photocoagulation, in eyes with focal diabetic macular edema, stratified per the location of thickening with optical coherence tomography. We evaluated people with type 2 diabetes and focal diabetic macular edema, before and three weeks after focal photocoagulation. Read More

Optom Vis Sci 2019 Apr;96(4):266-275

School of Optometry, University of California Berkeley, Berkeley, California.

Significance: The pathological changes in clinically significant diabetic macular edema lead to greater retinal thickening in men than in women. Therefore, male sex should be considered a potential risk factor for identifying individuals with the most severe pathological changes. Understanding this excessive retinal thickening in men may help preserve vision. Read More

J Ophthalmol 2019 17;2019:8216150. Epub 2019 Feb 17.

Assistant Professor of Ophthalmology, Ain Shams University, Cairo, Egypt.

Purpose: To compare outer retinal layer (ORL) thickness and photoreceptor outer segment (PROS) length between normal eyes and eyes with diabetic macular edema (DME), and also, to study the correlation between central macular thicknesses (CMT), ORL, and PROS length with best corrected visual acuity (BCVA) in DME.

Methods: 80 eyes were included in the study; they were divided into two groups, group Ι (40 normal eyes) and group ΙΙ (40 eyes) with DME. Complete ophthalmic examination and OCT were done for all eyes. Read More

Ophthalmology 2019 Mar 21. Epub 2019 Mar 21.

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Purpose: The aim of the phase 2 BOULEVARD study was to compare the safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME).

Design: BOULEVARD (NCT02699450) was a prospective, randomized, active comparator-controlled, double-masked, multicenter, phase 2 study conducted at 59 sites in the United States.

Participants: The trial enrolled patients aged ≥18 years with center-involving DME, best-corrected visual acuity (BCVA) 73-24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) ≥325 μm. Read More

Contemp Clin Trials 2019 May 21;80:34-39. Epub 2019 Mar 21.

Novartis Pharma AG, Basel, Switzerland; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany. Electronic address:

Background: Ranibizumab and aflibercept are anti-vascular endothelial growth factor therapies for diabetic macular edema (DME) but have only been directly compared in one study: the Protocol T study, a 24-month randomized controlled trial which compared the safety and efficacy of three anti-VEGF agents (ranibizumab 0.3 mg, aflibercept 2.0 mg and bevacizumab 1. Read More

Exp Eye Res 2019 Mar 21;182:57-64. Epub 2019 Mar 21.

Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address:

Human eyes may develop different vascular diseases with neovascularization and/or leakage, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), retinopathy of prematurity, corneal neovascularization and intraocular tumors. A breakthrough in therapy is the advent and approval of vascular endothelial growth factor (VEGF) inhibitors. However, anti-VEGF drugs not only have limited efficacy to treat AMD, DME and PDR but also are not approved for other ocular indications. Read More

Acta Diabetol 2019 Mar 22. Epub 2019 Mar 22.

Department of Ophthalmology, University Hospital Leipzig, Liebigstr. 10-14, 04103, Leipzig, Germany.

Aims: To describe and compare the functional and anatomical outcomes of untreated and treated diabetic macular edema (DME) in eyes with very good baseline visual acuity (VA) in a real-world setting.

Methods: A 12-month, retrospective, multicenter, observational cohort study, including DME patients with baseline visual acuity (VA) ≤ 0.1 logMAR (≥ 20/25 Snellen) and central subfield thickness (CST) > 250 µm with intra- and/or subretinal fluid seen on optical coherence tomography. Read More

Retina 2019 Mar 11. Epub 2019 Mar 11.

Kayseri City Training and Research Hospital, Kocasinan, Kayseri, Turkey.

Purpose: To investigate the effect of age on aflibercept (Eylea) response in macular edema secondary to treatment-naive diabetic eyes.

Methods: Two hundred seventy-three eyes of 273 treatment-naive patients with macular edema secondary to diabetes mellitus were enrolled in this study. The patients in the study were divided into the following 4 groups according to their ages: Group 1 (40-50 years), Group 2 (51-60 years), Group 3 (61-70 years), and Group 4 (>70 years). Read More

J Ocul Pharmacol Ther 2019 Mar 21. Epub 2019 Mar 21.

Department of Ophthalmology, Medical Faculty, Ondokuz Mayis University, Samsun, Turkey.

Purpose: To determine the role of baseline characteristics in predicting visual outcome in patients with diabetic macular edema (DME) treated with ranibizumab.

Methods: A review was carried out of the charts of 97 eyes that received pro re nata (PRN) intravitreal ranibizumab (IR) 0.5 mg treatment for DME. Read More

Ophthalmic Surg Lasers Imaging Retina 2019 Mar;50(3):167-173

Background And Objective: To evaluate the effect of baseline factors on differences in vision gains with intravitreal aflibercept injection (IAI) versus laser control in patients with diabetic macular edema (DME).

Patients And Methods: This was an integrated post-hoc subanalysis of two phase 3 trials (VISTA, VIVID) in patients with DME. Least square (LS) mean differences of patients treated with IAI compared to laser control in best-corrected visual acuity (BCVA) change from baseline at week 100 were evaluated for association with baseline demographics and baseline systemic disease characteristics. Read More

Rom J Ophthalmol 2018 Oct-Dec;62(4):260-269

OcuCenter Ophthalmological Clinic, Cluj-Napoca, Romania.

The authors are discussing over 80 articles that they have published in the last 5 years in the renowned ophthalmic journals worldwide, which have approached, for the first time in the ophthalmic literature, the following 4 topics: the acute central/ hemicentral retinal vein occlusion, the therapeutic interventions in the fellow eye of patients with unilateral malignant glaucoma, the persistent diabetic macular edema, and the current researches in patients with neovascular age-related macular degeneration. Read More

Heliyon 2019 Feb 28;5(2):e01271. Epub 2019 Feb 28.

Department of Computing, University of A Coruña, 15071, A Coruña, Spain.

Optical Coherence Tomography (OCT) constitutes an imaging technique that is increasing its popularity in the ophthalmology field, since it offers a more complete set of information about the main retinal structures. Hence, it offers detailed information about the eye fundus morphology, allowing the identification of many intraretinal pathological signs. For that reason, over the recent years, Computer-Aided Diagnosis (CAD) systems have spread to work with this image modality and analyze its information. Read More

World J Diabetes 2019 Mar;10(3):140-153

Department of Ophthalmology, University of Health Sciences, Ulucanlar Eye Training and Research Hospital, Ankara 06240, Turkey.

Diabetes mellitus (DM) is a chronic systemic disease that has increases in prevalence over time. DM can affect all ocular structures, with cataract being the most common ocular complication. Cataract is the leading cause of blindness worldwide. Read More

Sci Rep 2019 Mar 18;9(1):4806. Epub 2019 Mar 18.

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Diabetic retinopathy (DR) induces the breakdown of the blood-retinal barrier and promotes neuroinflammation, although autoimmune responses to sequestered retinal antigens remain poorly understood. In this study, we investigated the autoantibodies for retinal antigens in sera from diabetic macular edema (DME) patients. Screening by immunoblotting demonstrated that IgG from 7 of 10 DME sera samples reacted to an ~102-kDa autoantigen from porcine retinas. Read More

Eur J Ophthalmol 2019 Mar 18:1120672119834474. Epub 2019 Mar 18.

16 Augenpraxisklinik Konstanz, Konstanz, Germany.

Introduction:: The Retro-IDEAL (ILUVIEN Implant for chronic DiabEtic MAcuLar edema) study is a retrospective study designed to assess real-world outcomes achieved with the ILUVIEN® (0.19 mg fluocinolone acetonide (FAc)) in patients with chronic diabetic macular edema (DME) in clinical practices in Germany.

Methods:: This study was conducted across 16 sites in Germany and involved 81 eyes (63 patients) with persistent or recurrent DME and a prior suboptimal response to a first-line intravitreal therapy (primarily anti-VEGF intravitreal therapies). Read More

Qual Life Res 2019 Mar 16. Epub 2019 Mar 16.

Singapore Eye Research Institute (SERI), The Academia, 20 College Road, Level 6, Singapore, 169856, Singapore.

Importance: Previous work has reported a link between diabetic retinopathy/diabetic macular edema (DR/DME) and psychosocial functioning, although the extent and direction of the association remains uncertain.

Objective: To determine the relationship between DR/DME and psychosocial functioning, the latter an umbrella term used to capture the emotional and social aspects of functioning which may include, for example, depression; depressive disorder; anxiety; vision-specific distress; diabetes-specific distress and emotional and social well-being.

Evidence Review: PubMed, Embase, Medline and the Cochrane Central register were systematically searched for relevant interventional and observational quantitative studies using standardised criteria. Read More

Am J Ophthalmol 2019 Mar 13. Epub 2019 Mar 13.

University of Michigan, Kellogg Eye Center, Department of Ophthalmology and Visual Sciences.

Purpose: To illustrate that patients with diabetic retinopathy who are treated exclusively with anti-VEGF therapy and have an interruption in treatment may experience marked progression of disease with potentially devastating visual consequences.

Design: Retrospective, multicenter, case series METHODS: Retrospective review of patients treated exclusively with anti-VEGF therapy for proliferative (PDR) or non-proliferative diabetic retinopathy (NPDR), with or without diabetic macular edema (DME), and temporarily lost to follow-up. Baseline disease characteristics, cause and duration of the treatment interruption, and resulting disease progression, complications, and outcomes were assessed. Read More

Clin Ophthalmol 2019 15;13:373-381. Epub 2019 Feb 15.

Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan,

Purpose: To determine the effect of intravitreal aflibercept injection on the corneal endothelium in patients with diabetic or cystoid macular edema caused by retinal vein occlusion.

Material And Methods: Forty-six eyes of 44 consecutive patients (27 men, 17 women; age range: 55-88 years) were evaluated. All participants initially received a single intravitreal injection of aflibercept (2 mg in 0. Read More

J Fr Ophtalmol 2019 Mar 8;42(3):288-294. Epub 2019 Mar 8.

Département d'ophtalmologie, faculté de médecine, Université Saint-Joseph de Beyrouth, Liban.

Introduction: Diabetic retinopathy (DR) is a leading cause of blindness worldwide. Non-mydriatic fundus photography (NMFP) has been adopted as a screening tool for this disease. We aim to determine the prevalence of DR through this method in Lebanese diabetic patients and to evaluate the impact of such screening in this population. Read More

Eur J Ophthalmol 2019 Mar 11:1120672119830578. Epub 2019 Mar 11.

15 Department of Ophthalmology, University of Firenze, Florence, Italy.

Background:: The purpose of this study is to determine the prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy.

Methods:: It is a prospective, multicenter, cross-sectional study. Thirteen ophthalmic units equally distributed across the Italian territory have been involved in the study. Read More

Sci Rep 2019 Mar 7;9(1):3799. Epub 2019 Mar 7.

Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.

Diabetic retinopathy (DR) is a major cause of blindness in working adults in the industrialized world. In addition to vision loss caused by macular edema and pathological angiogenesis, DR patients often exhibit neuronal dysfunction on electrophysiological testing, suggesting that there may be an independent neuronal phase of disease that precedes vascular disease. Given the tremendous metabolic requirements of the retina and photoreceptors in particular, we hypothesized that derangements in metabolic regulation may accelerate retinal dysfunction in diabetes. Read More

Sci Rep 2019 Mar 6;9(1):3703. Epub 2019 Mar 6.

Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.

The current study aimed to address whether ripasudil, a Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor developed to treat glaucoma and ocular hypertension (OH), improves diabetic macular edema (DME) since it is known that ROCK upregulates vascular endothelial growth factor. We retrospectively investigated the foveal thickness (FT) measured by spectral-domain optical coherence tomography, visual acuity (VA), and intraocular pressure (IOP) in 12 eyes with DME that received ripasudil treatment for primary open-angle glaucoma or OH and compared them with 14 eyes that received no treatment. One month after ripasudil therapy, the mean FT decreased significantly from 439 ± 72 µm to 395 ± 62 µm (P = 0. Read More